Achievement of Cure with Gefitinib in Advanced Lung Adenocarcinoma Harboring an Activating EGFR Mutation: A Case Report

Achievement of Cure with Gefitinib in Advanced Lung Adenocarcinoma Harboring an Activating EGFR Mutation: A Case Report

Tyrosine kinase inhibitors (TKIs) of the epidermal growth factor receptor (EGFR) may achieve long-term survival in selected cases with advanced non-small cell lung cancer harboring activating mutations in the EGFR gene, but a cured case has not been reported yet. Here, we present the first case of E...

Fuld beskrivelse

Bibliografiske detaljer
Main Authors:	Taiji Kuwata, Kazue Yoneda, Kenichi Kobayashi, Rintarou Oyama, Hiroki Matumiya, Shuichi Shinohara, Masaru Takenaka, Soichi Oka, Yasuhiro Chikaishi, Naoko Imanishi, Koji Kuroda, Fumihiro Tanaka
Format:	Article
Sprog:	English
Udgivet:	Karger Publishers 2016-10-01
Serier:	Case Reports in Oncology
Fag:	Lung cancer EGFR mutation EGFR TKI
Online adgang:	http://www.karger.com/Article/FullText/449371

Lignende værker

FBXW7 deletion contributes to lung tumor development and confers resistance to gefitinib therapy
af: Yi Xiao, et al.
Udgivet: (2018-06-01)

Extracellular Vesicle miR-200c Enhances Gefitinib Sensitivity in Heterogeneous EGFR-Mutant NSCLC
af: Chien-Chung Lin, et al.
Udgivet: (2021-02-01)

Impact of the generation of EGFR‐TKIs administered as prior therapy on the efficacy of osimertinib in patients with non‐small cell lung cancer harboring EGFR T790M mutation
af: Yosuke Miyashita, et al.
Udgivet: (2021-02-01)

Comprehensive profiling of EGFR mutation subtypes reveals genomic-clinical associations in non-small-cell lung cancer patients on first-generation EGFR inhibitors
af: Yongkang Bai, et al.
Udgivet: (2023-04-01)

Efficacy and Safety of Chemotherapy or EGFR‐TKIs as First‐Line Therapy in NSCLC Patients Harboring Non‐Ex 20 Ins Uncommon EGFR Mutations: A Retrospective Study in China
af: Chen Liao, et al.
Udgivet: (2025-01-01)

A Large Real-World Study on the Effectiveness of the Combined Inhibition of EGFR and MET in EGFR-Mutant Non-Small-Cell Lung Cancer After Development of EGFR-TKI Resistance
af: Li Liu, et al.
Udgivet: (2021-10-01)

The Efficacy and Safety of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Combined With Thymosin in Advanced Non-Small Cell Lung Cancer Patients Harboring Active Epidermal Growth Factor Receptor Mutations
af: Yongdong Feng, et al.
Udgivet: (2021-05-01)

Radiolabeled EGFR TKI as predictive imaging biomarkers in NSCLC patients – an overview
af: Eveline Van De Stadt, et al.
Udgivet: (2022-10-01)

Combining EGFR-TKI With SAHA Overcomes EGFR-TKI-Acquired Resistance by Reducing the Protective Autophagy in Non-Small Cell Lung Cancer
af: Peijun Cao, et al.
Udgivet: (2022-03-01)

Addition of bevacizumab to EGFR tyrosine kinase inhibitors in advanced NSCLC: an updated systematic review and meta-analysis
af: Haosheng Zheng, et al.
Udgivet: (2024-01-01)

Afatinib After Progression on Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer
af: Jacqueline V Aredo, et al.
Udgivet: (2022-01-01)

Efficacy of dacomitinib in patients with EGFR‐mutated NSCLC and brain metastases
af: Jinyao Zhang, et al.
Udgivet: (2021-12-01)

The prognostic impact of neutrophil to lymphocyte ratio in advanced non-small-cell lung cancer patients treated with EGFR TKI
af: Phan TT, et al.
Udgivet: (2018-11-01)

EGFR‐mutated stage IV non‐small cell lung cancer: What is the role of radiotherapy combined with TKI?
af: Bailong Liu, et al.
Udgivet: (2021-09-01)

ORIENT-31 as the Sakigake “Charging Samurai” Born of IMpower150 but Will MARIPOSA-2 IMPRESS in the “Meiji Modernization” of Post-3G EGFR TKI Progression?
af: Nagasaka M, et al.
Udgivet: (2022-03-01)

Real-world Treatment Patterns in Patients with EGFR Mutation-positive NSCLC Receiving a First-Line, First- or Second-generation EGFR Tyrosine Kinase Inhibitor in South Korea and Taiwan
af: Jae Cheol Lee, et al.
Udgivet: (2021-05-01)

Analysis of tumor abnormal protein expression and epidermal growth factor receptor mutation status in non-small cell lung cancer
af: Yuanjun Cheng, et al.
Udgivet: (2024-07-01)

Reprogramming of Lipid Metabolism in Lung Cancer: An Overview with Focus on EGFR-Mutated Non-Small Cell Lung Cancer
af: Kamal Eltayeb, et al.
Udgivet: (2022-01-01)

Utilisation Patterns and Treatment Outcomes of EGFR-Tyrosine Kinase Inhibitors in EGFR-mutant Advanced Lung Carcinoma in the Pakistani-Asian Population: A Real-world Data Study
af: Kiran Munawar, et al.
Udgivet: (2022-11-01)

Patients harboring uncommon EGFR exon 19 deletion-insertion mutations respond well to first-generation EGFR inhibitors and osimeritinib upon acquisition of T790M
af: Yurong Wang, et al.
Udgivet: (2021-11-01)

Larotinib in patients with advanced and previously treated esophageal squamous cell carcinoma with epidermal growth factor receptor overexpression or amplification: an open-label, multicenter phase 1b study
af: Rongrui Liu, et al.
Udgivet: (2021-10-01)

A good response to furmonertinib fourth-line treatment of an advanced lung adenocarcinoma patient with EGFR exon20in and PIK3CA mutation: a case report and literature review
af: Kai Sun, et al.
Udgivet: (2024-12-01)

Lung adenocarcinoma presents with diffuse bone metastasis
af: Jinye Mi, et al.
Udgivet: (2021-10-01)

Epidermal growth factor receptor-mutated non-small-cell lung cancer: A primer on contemporary management
af: Akhil Rajendra, et al.
Udgivet: (2019-01-01)

Clinical Developments for the EGFR-TKI Combined with Radiotherapy in Advanced Non-small Cell Lung Cancer
af: Xianan LI, et al.
Udgivet: (2014-04-01)

Prognostic Value of Albumin-to-Alkaline Phosphatase Ratio for EGFR-Mutated Advanced Non-Small-Cell Lung Cancer Patients Treated with First-Line EGFR-TKIs: A Large Population-Based Study and Literature Review
af: Gan Y, et al.
Udgivet: (2022-03-01)

Effects of Erlotinib on 34 Patients with Advanced Squamous Cell Lung Cancer
af: Fang CHENG, et al.
Udgivet: (2016-10-01)

EGFR-TKI plus bevacizumab versus EGFR-TKI monotherapy for patients with EGFR mutation-positive advanced non-small cell lung cancer-A propensity score matching analysis
af: Jeng-Shiuan Tsai, et al.
Udgivet: (2021-09-01)

pSTAT3 transactivates EGFR in maintaining EGFR protein homeostasis and EGFR-TKI resistance
af: Ao Juan, et al.
Udgivet: (2024-09-01)

Characteristics of Long-Term Survivors With EGFR-Mutant Metastatic NSCLC
af: William Tompkins, MD, et al.
Udgivet: (2024-08-01)

Tissue or liquid rebiopsy? A prospective study for simultaneous tissue and liquid NGS after first‐line EGFR inhibitor resistance in lung cancer
af: Yen‐Ting Lin, et al.
Udgivet: (2024-01-01)

Induction EGFR tyrosine kinase inhibitors prior to definitive chemoradiotherapy in unresectable stage III EGFR-mutated non-small cell lung cancer
af: Jacqueline V. Aredo, et al.
Udgivet: (2022-01-01)

The Prediction Of Epidermal Growth Factor Receptor Mutation And Prognosis Of EGFR Tyrosine Kinase Inhibitor By Serum Ferritin In Advanced NSCLC
af: Wu Z, et al.
Udgivet: (2019-10-01)

Higher osimertinib introduction rate achieved by multiple repeated rebiopsy after acquired resistance to first/second generation EGFR‐TKIs
af: Taira Ninomaru, et al.
Udgivet: (2021-03-01)

Growth Suppression in Lung Cancer Cells Harboring EGFR-C797S Mutation by Quercetin
af: Kuo-Yen Huang, et al.
Udgivet: (2021-08-01)

Epidermal growth factor receptor inhibitors as adjuvant treatment for patients with resected non-small cell lung cancer harboring EGFR mutation: a meta-analysis of randomized controlled clinical trials
af: Ning Zhao, et al.
Udgivet: (2023-02-01)

Results of the phase IIa study to evaluate the efficacy and safety of rezivertinib (BPI-7711) for the first-line treatment of locally advanced or metastatic/recurrent NSCLC patients with EGFR mutation from a phase I/IIa study
af: Yuankai Shi, et al.
Udgivet: (2023-01-01)

Potential Therapeutic Strategy for EGFR-Mutant Lung Cancer With Concomitant EML4-ALK Rearrangement—Combination of EGFR Tyrosine Kinase Inhibitors and ALK Inhibitors
af: Ming-Hung Huang, PhD, et al.
Udgivet: (2022-11-01)

Resistance to Both Chemotherapy and EGFR-TKI in Small Cell Lung Cancer With EGFR 19-Del Mutation: A Case Report
af: Lingfei Wang, et al.
Udgivet: (2020-07-01)

Afatinib in EGFR TKI-Naïve Patients with Locally Advanced or Metastatic EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Pooled Analysis of Three Phase IIIb Studies
af: Antonio Passaro, et al.
Udgivet: (2021-07-01)